CO6190532A2 - Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4 - Google Patents

Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4

Info

Publication number
CO6190532A2
CO6190532A2 CO09010461A CO09010461A CO6190532A2 CO 6190532 A2 CO6190532 A2 CO 6190532A2 CO 09010461 A CO09010461 A CO 09010461A CO 09010461 A CO09010461 A CO 09010461A CO 6190532 A2 CO6190532 A2 CO 6190532A2
Authority
CO
Colombia
Prior art keywords
group
amino
pde4
alkoxy
methods
Prior art date
Application number
CO09010461A
Other languages
English (en)
Spanish (es)
Inventor
Steven Govek
Andrew Shiau
Stewart Noble
David J Thomas
Original Assignee
Steven Govek
Andrew Shiau
Stewart Noble
David J Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steven Govek, Andrew Shiau, Stewart Noble, David J Thomas filed Critical Steven Govek
Publication of CO6190532A2 publication Critical patent/CO6190532A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO09010461A 2006-07-07 2009-02-04 Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4 CO6190532A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81950906P 2006-07-07 2006-07-07
US88682507P 2007-01-26 2007-01-26

Publications (1)

Publication Number Publication Date
CO6190532A2 true CO6190532A2 (es) 2010-08-19

Family

ID=38739981

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09010461A CO6190532A2 (es) 2006-07-07 2009-02-04 Inhibidores heteroaril biciclicos de pde4, metodos para su sintesis y metodos para inhibir pde4

Country Status (11)

Country Link
US (5) US8080563B2 (enExample)
EP (1) EP2037924A2 (enExample)
JP (2) JP5280357B2 (enExample)
KR (2) KR20090109527A (enExample)
CN (1) CN104606194A (enExample)
AU (1) AU2007269070B2 (enExample)
BR (1) BRPI0713253A2 (enExample)
CA (1) CA2657093A1 (enExample)
CO (1) CO6190532A2 (enExample)
MX (1) MX2009000148A (enExample)
WO (3) WO2008006051A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2003078448A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
EA009985B1 (ru) 2003-03-10 2008-04-28 Никомед Гмбх Новый способ получения рофлумиласта
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
ES2421916T3 (es) 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
US8080563B2 (en) 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
CN102014897B (zh) 2008-04-21 2015-08-05 西格纳姆生物科学公司 化合物、组合物和其制备方法
CN101353338B (zh) * 2008-07-10 2011-05-04 上海交通大学 糖胺改性的水溶性香豆素酮衍生物及其制备方法
US20110082145A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
US8394829B2 (en) 2010-05-10 2013-03-12 Gilead Sciences, Inc. Bi-functional quinoline analogs
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
US20130116279A1 (en) * 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
MD20150071A2 (ro) 2013-02-19 2016-02-29 Pfizer Inc. Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
EA031201B1 (ru) 2014-08-06 2018-11-30 Пфайзер Инк. Соединения имидазопиридазина
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CN106916104B (zh) * 2017-02-28 2019-08-27 牡丹江医学院 用于治疗结肠炎的药物
EP3658167A1 (en) * 2017-07-26 2020-06-03 HG&H Pharmaceuticals (Pty) Limited Mesembrenol and/or mesembranol for prophylaxis and treatment of patients suffering from epilepsy and associated diseases
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
US20220098257A1 (en) * 2019-01-23 2022-03-31 Path Therapeutics, Inc. Methods of Treating Epilepsy via Phosphodiesterase 4 (PDE4) Inhibition
US12630501B2 (en) 2019-09-08 2026-05-19 Hadasit Medical Research Services And Development Ltd. Anti-fibrotic compounds and use thereof
CN116507336B (zh) * 2020-09-10 2026-01-02 Vanda制药公司 治疗pde iv介导的疾病或病症的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US542104A (en) * 1895-07-02 Nut-sheller
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
JP2673024B2 (ja) * 1988-01-15 1997-11-05 アボツト・ラボラトリーズ アミノメチル‐クロマン及び‐チオクロマン化合物
AU8665991A (en) 1990-09-07 1992-03-30 Schering Corporation Antiviral compounds and antihypertensive compounds
WO1992017452A1 (en) 1991-04-03 1992-10-15 Korea Research Institute Of Chemical Technology 2-quinolinone derivatives
JPH08503484A (ja) 1992-11-27 1996-04-16 ビイク ネダーラント ベスローテン フェンノートシャップ 調剤学的特性を有するニトロキシ化合物
FR2703683B1 (fr) 1993-04-08 1995-07-07 Seractec Dérivés d'aminocoumarines hydrophobes, et leur utilisation comme substrats d'enzymes protéolytiques ou pour la préparation de tels substrats.
FR2711992A1 (fr) 1993-11-03 1995-05-12 Lipha Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant.
DE4337906A1 (de) 1993-11-08 1995-05-11 Cassella Ag Verwendung von Cumarinderivaten
US5563280A (en) * 1994-07-25 1996-10-08 American Cyanamid Co. 4-Phenoxycoumarins as herbicidal agents
IL123701A (en) * 1995-10-13 2002-03-10 Agrevo Uk Ltd Heterocyclic fungicides and a number of new compounds
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
US20040081959A9 (en) * 1999-12-08 2004-04-29 Epoch Biosciences, Inc. Fluorescent quenching detection reagents and methods
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
US6436971B2 (en) * 2000-02-09 2002-08-20 Smithkline Beecham Corporation Use of PDE 4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
DE10021256A1 (de) * 2000-04-20 2001-10-31 Forschungsverbund Berlin Ev Neue, photolabile Cumarinylmethylester von cyclischen Nucleotiden, Verfahren zu deren Herstellung und ihre Verwendung
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
JP2002371078A (ja) 2001-06-12 2002-12-26 Sankyo Co Ltd キノリン誘導体及びキノロン誘導体
JP2003146972A (ja) * 2001-11-14 2003-05-21 Teikoku Hormone Mfg Co Ltd カルボスチリル誘導体
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
US7148253B2 (en) * 2002-05-14 2006-12-12 Xtl Biopharmaceuticals Ltd. 4-thio coumarins
WO2003097628A1 (en) 2002-05-14 2003-11-27 Vivoquest, Inc. 4-thio coumarins
AU2003263814A1 (en) * 2002-07-26 2004-02-16 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
CN1506359A (zh) * 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
ITMI20022739A1 (it) * 2002-12-23 2004-06-24 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4.
WO2005028472A1 (en) * 2003-09-15 2005-03-31 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods of treatment therewith
EP1718306A2 (en) 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
ATE531705T1 (de) * 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
MX2007003375A (es) 2004-09-22 2007-05-07 Janssen Pharmaceutica Nv Inhibidores de la interaccion entre mdm2 y p53.
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
NL1028569C2 (nl) 2005-03-18 2006-09-20 Rademaker Holding B V Toepassing van een coumarine-groep omvattende derivaten voor de bereiding van een antiviraal middel, alsmede kattenvoer.
US8048889B2 (en) * 2005-03-29 2011-11-01 Xtl Biopharmaceuticals Ltd. 3,4-disubstituted coumarin and quinolone compounds
ES2399061T3 (es) 2005-09-30 2013-03-25 Pulmagen Therapeutics (Asthma) Limited Quinolinas y su uso terapéutico
US8080563B2 (en) * 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
US8138205B2 (en) * 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
US20130116279A1 (en) * 2011-11-07 2013-05-09 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4

Also Published As

Publication number Publication date
US20100022586A1 (en) 2010-01-28
US7745646B2 (en) 2010-06-29
MX2009000148A (es) 2009-10-26
EP2037924A2 (en) 2009-03-25
JP5705269B2 (ja) 2015-04-22
WO2008006052A3 (en) 2008-11-20
JP2009542815A (ja) 2009-12-03
CN104606194A (zh) 2015-05-13
AU2007269070A1 (en) 2008-01-10
WO2008006050A2 (en) 2008-01-10
AU2007269070B2 (en) 2013-03-21
CA2657093A1 (en) 2008-01-10
JP5280357B2 (ja) 2013-09-04
US8080563B2 (en) 2011-12-20
US8258154B2 (en) 2012-09-04
US20130178498A1 (en) 2013-07-11
WO2008006050A3 (en) 2008-06-26
WO2008006051A2 (en) 2008-01-10
US9078887B2 (en) 2015-07-14
WO2008006052A2 (en) 2008-01-10
KR20150004441A (ko) 2015-01-12
US20080027099A1 (en) 2008-01-31
BRPI0713253A2 (pt) 2012-10-30
US20080027112A1 (en) 2008-01-31
JP2013177421A (ja) 2013-09-09
KR20090109527A (ko) 2009-10-20
WO2008006051A3 (en) 2008-06-26
US20090291950A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
WO2009005152A1 (ja) 新規脂質トリペプチド性ヒドロゲル化剤及びヒドロゲル
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
TN2009000012A1 (en) Amino-piperidine derivatives as cetp inhibitors
EA200300568A1 (ru) Гетероциклилалкилпиперидиновые производные, способ их получения и содержащие их композиции
JO3116B1 (ar) مشتق بيرازولوكينولين كمثبطات ل pde9
MX2009006598A (es) Derivados de sulfamida como transferasa de carnitina palmitoil del higado (l-cptl).
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
ECSP055883A (es) Nuevos derivados de piridazin-3(2h)-ona
TW200642683A (en) Heterocyclic compound
NO20082630L (no) Vann-opploslige benzoazepinforbindelser og farmasoytisk forbindelse
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
GB2570549A8 (en) Acid gas absorbent, acid gas removal method, and acid gas removal device
IL187409A0 (en) Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l- cpt1) inhibitors
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
MX2011011281A (es) Compuesto de carbinol que tiene un enlazante heterociclico.
MX2010006446A (es) Nuevos derivados de diazeniodiolato, procedimiento para la preparacion de los mismos y composiciones farmaceuticas que los contienen.
EA200700360A1 (ru) Новые производные амида гетероциклической карбоновой кислоты
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica
EA200101230A1 (ru) Новые ингибиторы металлопротеаз, метод их получения и содержащие их фармацевтические композиции
CR8340A (es) Pirazolilcarboxanilidas n-sustituidas
CY1115138T1 (el) Παραγωγο 3,8-διαμινοτετραϋδροκινολινης

Legal Events

Date Code Title Description
FG Application granted